Scilex Holding Company (SCLX)

NASD · Healthcare · Drug Manufacturers - General · USA

Scilex Holding Company is a micro cap company (market value under $300 million) in the Drug Manufacturers - General industry.

Scilex Holding Company acquires and commercializes non-opioid pain management products. The company markets three approved products: ZTlido, a prescription lidocaine topical system for neuropathic pain; ELYXYB, an oral solution for acute migraine; and GLOPERBA, a liquid colchicine formulation for gout. Scilex also develops product candidates targeting sciatica and fibromyalgia.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Scilex Holding Company stock.

Our verdict on SCLX

Not valued: We cannot value this company yet.

We do not publish a value for this company: not even its current assets cover what it owes.

ETFs with the most weight in SCLX

3 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Drug Manufacturers - General

All 21 Drug Manufacturers - General stocks

Cheaper than SCLX in Drug Manufacturers - General

9 more in this industry show a wider margin of safety.

Is SCLX undervalued or overvalued?

We do not publish a verdict on SCLX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of SCLX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.